Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
46 hedge funds and large institutions have $28M invested in Finch Therapeutics Group, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
13% less funds holding
Funds holding: 53 → 46 (-7)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
47% less capital invested
Capital invested by funds: $53.1M → $28M (-$25.1M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$641K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$615K |
| 3 |
Millennium Management
New York
|
+$260K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$151K |
| 5 |
Goldman Sachs
New York
|
+$98.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSCM
Light Street Capital Management
Palo Alto,
California
|
-$3.36M |
| 2 |
BlackRock
New York
|
-$964K |
| 3 |
State Street
Boston,
Massachusetts
|
-$242K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$189K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$162K |
FNCH Hedge Fund Activity: Q2 2022 in Review
46 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q2 2022, worth a combined $28M — down 47% from $53.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of FNCH and 8 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was Oasis Management Company, opening a new position worth an estimated $641K. The largest seller was Light Street Capital Management, exiting entirely with an estimated $3.36M sold.
- 46 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q2 2022, down from 53 in Q1 2022.
- Funds reported $28M of Finch Therapeutics Group, Inc. Common Stock stock for Q2 2022, down 47% quarter-over-quarter.
- 8 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q2 2022 and 14 closed out, a net change of -6 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q2 2022 was Oasis Management Company, an estimated $641K added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q2 2022 was Light Street Capital Management, an estimated $3.36M sold.
Based on aggregated 13F filings for Q2 2022.